Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Starpharma signs agrochemicals deal

Abstract:
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing of a research and collaboration agreement between its wholly owned US subsidiary, DNT Inc, and a prominent, US-based agricultural chemicals company. The confidentiality provisions of the agreement prevent disclosure of the name of the collaborating company at this time.

Starpharma signs agrochemicals deal

Melbourne, Australia; | Posted on November 5th, 2009

Under the agreement the parties will use DNT's Priostar® dendrimer technology to enhance the performance of existing pesticides. The approach is a natural extension of Starpharma's drug delivery work, in which dendrimers extend the persistence of an active molecule, potentially reducing the amount of active that is required for a given effect.

The agreement applies to specific classes of pesticides, and does not prevent Starpharma's further commercialisation of dendrimers more widely in the agricultural chemicals sector. The global market for agricultural chemicals for 2008 was estimated to be US$123.5 billion, of which pesticides represented US$35.8 billion.

"Agricultural applications offer an exciting and significant opportunity for the Company in what is a completely new market for Starpharma's proprietary technology," said Dr Jackie Fairley, CEO Starpharma.

"Starpharma is committed to building its revenues through partnering with market leaders in selected, commercially attractive industry sectors, as this deal and our previous partnerships illustrate. This strategy allows us to rely on partners' product knowledge and market position to rapidly achieve diversification of our commercial base, whilst enabling the Company to focus its own resources on its core competencies and lead products," Dr Fairley added.

Starpharma's other areas of commercial exploitation of dendrimer technology include: sexual health (VivaGel® coated condoms - licensed to SSL International, and VivaGel® topical microbicide); drug delivery with GSK's Stiefel laboratories; in vitro diagnostics through Siemens Healthcare; laboratory reagents through Qiagen and EMD Merck; and animal health through Eli Lilly's Elanco.

American Depositary Receipts (ADRs): Starpharma's ADRs trade under the code SPHRY (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Securities Exchange (ASX). The Bank of New York Mellon is the depositary bank. Starpharma's ADRs are listed on International OTCQX (www.otcqx.com), a premium market tier in the U.S. for international exchange-listed companies, operated by Pink OTC Markets, Inc.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer technology for pharmaceutical, life-science and other applications. SPL has two operating companies, Starpharma Pty Ltd in Melbourne, Australia and DNT, Inc in the USA. Products based on SPL’s dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents through licence arrangements with partners including Siemens and Merck KgA. The Company’s lead pharmaceutical development product is VivaGel® (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. In September 2008 Starpharma signed a full licence agreement with SSL International plc (LSE:SSL) to develop a VivaGel® coated condom. SSL manufactures and sells Durex® condoms, the market-leading condom brand worldwide. Starpharma's receipts under the agreement are estimated to exceed A$100m comprising royalties on SSL sales, further milestone payments, and development support. In the wider pharmaceutical field Starpharma has specific programs in the areas of Drug Delivery and Drug Optimisation technologies (using dendrimers to control where and when drugs go when introduced to the body) and Targeted Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).

More broadly the company is exploring dendrimer opportunities in materials science applications including water remediation.

Dendrimer: A type of precisely-defined, branched particle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

For more information, please click here

Contacts:
Media Buchan Consulting
Rebecca Wilson
Tel: +61 3 9866 4722
Mob: +61 417 382 391


Starpharma
Ben Rogers
Company Secretary
+61 3 8532 2702

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Engineering a better 'Do: Purdue researchers are learning how August 4th, 2015

Proving nanoparticles in sunscreen products August 4th, 2015

Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015

Nanoparticles Give Antibacterial Properties to Machine-Woven Carpets August 4th, 2015

Products

Aculon Launches NanoProof Series for PCB Waterproofing July 20th, 2015

Philips Introduces Quantum Dot TV with Color IQ™ Technology from QD Vision: Manufacturer is first to offer quantum dot displays for both TVs and monitors June 30th, 2015

Dais Analytic Unveils New Version of Aqualyte Membrane Technology: Updates to the Basis of the Company's Industry-Changing Nanotechnology Designed to Strengthen Position in Global Air, Energy, and Water Markets June 26th, 2015

Industrial Nanotech, Inc. Announces Launch of Heat Shield(TM) EPX4 Thermal Insulation and Chemical Resistant Coating June 12th, 2015

Announcements

Engineering a better 'Do: Purdue researchers are learning how August 4th, 2015

Proving nanoparticles in sunscreen products August 4th, 2015

Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015

Nanoparticles Give Antibacterial Properties to Machine-Woven Carpets August 4th, 2015

Food/Agriculture/Supplements

Diagnosis of Salmonella Bacterium-Caused Food Poisoning by Biosensors August 3rd, 2015

Heating and cooling with light leads to ultrafast DNA diagnostics July 31st, 2015

Detecting small metallic contaminants in food via magnetization: A practical metallic-contaminant detecting system using three high-Tc RF superconducting quantum interference devices (SQUIDs) July 29th, 2015

QuantumSphere Completes State-of-the-Art Nanocatalyst Production Facility: Now Positioned to Capitalize on Commercial Validation and JDA with Casale, SA July 25th, 2015

Alliances/Trade associations/Partnerships/Distributorships

Harris & Harris Group Portfolio Company, HZO, Announces Partnerships with Dell and Motorola August 1st, 2015

The National Space Society Pays Tribute to Dr. Kalam -- One Of Our Leading Lights Has Joined The Stars August 1st, 2015

Liquipel Debuts Eyesight-Saving ION-Glass Blue Light Protection for iPhones and Androids at RadioShack Stores Nationwide: Liquipel's Unique Protective Screen, Available at RadioShack, Cuts Harmful Blue Light Implicated in Macular Degeneration by 10x July 28th, 2015

Dais Analytic's Business Affiliate in China Announces Ten-Year Strategic Energy Efficiency Business Arrangement With COFCO: Dais Beijing to Perform Feasibility Study on Over 80 Buildings to Improve Efficiencies as Part of Overall Hotel Energy-Savings Project July 23rd, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project